TBPH · As filed with the SEC
Theravance Biopharma cash flow statement, by quarter
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Operating activities | ||||
| Net income (loss) | — | (4,933,000) | — | — |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | 381,000 | — | — |
| Amortization and accretion on investment securities, net | — | (602,000) | — | — |
| Share-based compensation | — | 4,504,000 | — | — |
| Amortization of right-of-use assets | — | 1,056,000 | — | — |
| Deferred income taxes | — | (2,999,000) | — | — |
| Other | — | 42,000 | — | — |
| Changes in operating assets and liabilities: | ||||
| Receivables from collaborative and licensing arrangements | — | 29,954,000 | — | — |
| Receivables from milestones and royalty assets | — | 50,000,000 | — | — |
| Other prepaid and current assets | — | 1,666,000 | — | — |
| Right-of-use lease assets | — | 314,000 | — | — |
| Other assets | — | 1,025,000 | — | — |
| Accounts payable | — | (1,468,000) | — | — |
| Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities | — | (4,867,000) | — | — |
| Operating lease liabilities | — | (2,199,000) | — | — |
| Unrecognized tax benefits | — | 1,474,000 | — | — |
| Other long-term liabilities | — | (69,000) | — | — |
| Net cash provided by operating activities | — | 73,279,000 | — | — |
| Investing activities | ||||
| Purchases of marketable securities | — | (43,407,000) | — | — |
| Maturities of marketable securities | — | 96,000,000 | — | — |
| Net cash used in investing activities | — | 52,593,000 | — | — |
| Financing activities | ||||
| Proceeds from option exercises | — | 241,000 | — | — |
| Repurchase of shares to satisfy tax withholding | — | (5,818,000) | — | — |
| Net cash used in financing activities | — | (5,577,000) | — | — |
| Net increase in cash, cash equivalents, and restricted cash | — | 120,295,000 | — | — |
| Cash, cash equivalents, and restricted cash at beginning of period | 288,937,000 | 168,642,000 | 175,609,000 | 282,763,000 |
| Cash, cash equivalents, and restricted cash at end of period | 220,602,000 | 288,937,000 | 168,642,000 | 175,609,000 |
| Supplemental disclosure of cash flow information | ||||
| Cash paid (received) for income taxes, net | — | (351,000) | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.